Measurement and valuation of the attributes of innovation of healthcare technologies: a systematic review

References

• Vincent Rajkumar S. The high cost of prescription drugs: causes and solutions. Rochester: Nature Publishing Group; 2020. p. 1–5.
   Google Scholar
• Carrier MA. Higher drug prices from anticompetitive conduct: three case studies. J Leg Med. 2019;39(2):151–167.
   PubMed Web of Science ®Google Scholar
• Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. Lancet Regional Health–Europe. 2021;2021:3.
   Google Scholar
• Garrison LP, Jansen JP, Devlin NJ, et al. Novel approaches to value assessment within the cost-effectiveness framework. Value Health. 2019;22(6S):S12–S17.
   PubMedGoogle Scholar
• Garrison LP, Zamora B, Li M, et al. Augmenting cost-effectiveness analysis for uncertainty: the implications for value assessment—rationale and empirical support. J Manag Care Spec Pharm. 2020;26(4):400–406.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Jr Neumann PJ, Willke RJ, et al. A health economics approach to US value assessment frameworks—summary and recommendations of the ISPOR special task force report. Value Health. 2018;21(2):161–165.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP Jr, et al. Defining elements of value in health care- a health economics approach: an ISPOR special task force report. Value Health. 2018;21(2):131–139.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Jr Kamal-Bahl S, Towse A. Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health. 2017;20(2):213–216.
   PubMed Web of Science ®Google Scholar
• Li M. The real option value of life and innovation; 2018.
   Google Scholar
• Cleve M. What the lightning-fast quest for Covid vaccines means for other diseases. Nature. 2021;589:16–18.
   PubMed Web of Science ®Google Scholar
• Dolgin E. The tangled history of mRNA vaccines. Nature. 2021;597(7876):318–324.
   PubMed Web of Science ®Google Scholar
• Neergaard L. Years of research laid groundwork for speedy COVID-19 vaccines. PBS NewsHour; 2020.
   Google Scholar
• Neumann PJ, Garrison LP, Willke RJ. The history and future of the “ISPOR value flower”: addressing limitations of conventional cost-effectiveness analysis. Value Health. 2022;25(4):558–565.
   PubMed Web of Science ®Google Scholar
• Syeed MS, Poudel N, Ngorsuraches S, et al. Characterizing attributes of innovation of technologies for healthcare: a systematic review. J Med Econom. 2022;2022:1–12.
   Google Scholar
• Nicod E, Brigham KB, Durand-Zaleski I, et al. Dealing with uncertainty and accounting for social value judgments in assessments of orphan drugs: evidence from four European countries. Value Health. 2017;20(7):919–926.
   PubMed Web of Science ®Google Scholar
• Swinney DC, Lee JA. Recent advances in phenotypic drug discovery. F1000Res. 2020;9:944.
   Google Scholar
• Jonker CJ, van den Berg HM, Kwa MS, et al. Registries supporting new drug applications. Pharmacoepidemiol Drug Saf. 2017;26(12):1451–1457.
   PubMed Web of Science ®Google Scholar
• Miller KL, Lanthier M. Trends in orphan new molecular entities, 1983–2014: half were first in class, and rare cancers were the most frequent target. Health Aff. 2016;35(3):464–470.
   PubMed Web of Science ®Google Scholar
• Baum RA, Baum S. Interventional radiology: a half century of innovation. Radiology. 2014;273(2 Suppl):S75–S91.
   PubMedGoogle Scholar
• Joseph ML, Huber DL, Bair H, et al. A typology of innovations in nursing. J Nurs Adm. 2019;49(7–8):389–395.
   PubMed Web of Science ®Google Scholar
• de Solà-Morales O, Cunningham D, Flume M, et al. Defining innovation with respect to new medicines: a systematic review from a payer perspective. Int J Technol Assess Health Care. 2018;34(3):224–240.
   PubMed Web of Science ®Google Scholar
• Petykó ZI, Inotai A, Holtorf A-P, et al. Barriers and facilitators of exploiting the potential of value-added medicines. Expert Rev Pharmacoecon Outcomes Res. 2020;20(3):229–236.
   PubMed Web of Science ®Google Scholar
• Bryan S, Lee H, Mitton C. ‘Innovation’ in health care coverage decisions: all talk and no substance? J Health Serv Res Policy. 2013;18(1):57–60.
   PubMed Web of Science ®Google Scholar
• Roubou I, Alexopoulou DK. The various shapes of innovation. Forum Clin Oncol. 2015;6(4):12–22.
   Google Scholar
• Gashaw I, Ellinghaus P, Sommer A, et al. What makes a good drug target? Drug Discov Today. 2011;16(23–24):1037–1043.
   PubMed Web of Science ®Google Scholar
• Angelis A, Kanavos P. Multiple criteria decision analysis (MCDA) for evaluating new medicines in health technology assessment and beyond: the advance value framework. Soc Sci Med. 2017;188:137–156.
   PubMed Web of Science ®Google Scholar
• Consoli D, Mina A. An evolutionary perspective on health innovation systems. J Evol Econ. 2009;19(2):297–319.
   Web of Science ®Google Scholar
• Ellner AL, Stout S, Sullivan EE, et al. Health systems innovation at academic health centers: leading in a new era of health care delivery. Acad Med. 2015;90(7):872–880.
   PubMed Web of Science ®Google Scholar
• Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol. 2009;6(9):550–552.
   PubMed Web of Science ®Google Scholar
• Hamilton BH, Hincapié A, Miller RA, et al. Innovation and diffusion of medical treatment. St. Louis: National Bureau of Economic Research; 2018.
   Google Scholar
• Hübner U. What are complex eHealth innovations and how do you measure them? Methods Inf Med. 2015;54(4):319–327.
   PubMed Web of Science ®Google Scholar
• Ciani O, Armeni P, Boscolo PR, et al. De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making. Health Policy Technol. 2016;5(1):47–64.
   Web of Science ®Google Scholar
• Quinn C, Palmer S, Bruns J, Borras J, Grant C, Sykes D, editors. Innovation in oncology: Why focusing only on breakthrough innovation may be counter-productive. Pavia, Italy: Haematologica; 2015.
   Google Scholar
• Pammolli F, Riccaboni M. Market structure and drug innovation. Health Aff. 2004;23(1):48–50.
   PubMed Web of Science ®Google Scholar
• Council NC. NICE Citizens Council Reports. Health innovation and value. London: National Institute for Health and Care Excellence (NICE) Copyright © 2009 National Institute for Health and Clinical Excellence; 2009.
   Google Scholar
• McGloughlin EK, Anglim P, Keogh I, et al. Innovation for the future of Irish MedTech industry: retrospective qualitative review of impact of BioInnovate Ireland’s clinical fellows. BMJ Innov. 2018;4(1):32–38.
   PubMedGoogle Scholar
• Ferner R, Hughes DA, Aronson J. NICE and new: appraising innovation. BMJ. 2010;340(2):b5493–b5493.
   PubMedGoogle Scholar
• Quinn C, Palmer S, Bruns J, et al. Progressive innovation in oncology: valuing outcomes beyond survival. Value in Health. 2015;18(7):A482.
   Web of Science ®Google Scholar
• Sheard L, Jackson C, Lawton R. How is success achieved by individuals innovating for patient safety and quality in the NHS? BMC Health Serv Res. 2017;17(1):1–9.
   PubMedGoogle Scholar
• Mestre-Ferrandiz JM, Sussex J. The many faces of innovation. A report for the ABPI by the Office of Health Economics; 2012.
   Google Scholar
• Garrett MD, Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer. 1999;35(14):2010–2030.
   PubMed Web of Science ®Google Scholar
• Conti RM. The economic value of new treatments for depression [Doctoral dissertation]. Cambridge, MA: Harvard University; 2006.
   Google Scholar
• Fortinguerra F, Tafuri G, Trotta F, et al. Using GRADE methodology to assess innovation of new medicinal products in Italy. Br J Clin Pharmacol. 2020;86(1):93–105.
   PubMed Web of Science ®Google Scholar
• Costa LS. Innovation in healthcare services: notes on the limits of field research. Cadernos de saude publica. 2016;32:e00151915.
   Web of Science ®Google Scholar
• Chagpar AB. Innovation in surgery: from imagination to implementation. Am J Surg. 2011;202(6):641–645.
   PubMed Web of Science ®Google Scholar
• Biddiscombe MF, Usmani OS. Is there room for further innovation in inhaled therapy for airways disease? Breathe. 2018;14(3):216–224.
   Web of Science ®Google Scholar
• Chan TY, Hamilton BH, Papageorge NW. Health, risky behaviour and the value of medical innovation for infectious disease. Rev Economic Stud. 2016;83(4):1465–1510.
   Web of Science ®Google Scholar
• Bhatti Y, Taylor A, Harris M, et al. Global lessons in Frugal innovation to improve health care delivery in the United States. Health Aff. 2017;36(11):1912–1919.
   PubMed Web of Science ®Google Scholar
• Lakdawalla D, Malani A, Reif J. The insurance value of medical innovation. J Public Econ. 2017;145:94–102.
   Web of Science ®Google Scholar
• Papageorge NW. Essays in health, innovation and labor; 2012.
   Google Scholar
• Zaim R, Tran L, Groen H, et al. DE NOVO’ Quantification of genotype-directed therapy with Afatinib in metastatic lung cancer. Value Health. 2014;17(7):A641.
   PubMed Web of Science ®Google Scholar
• Djupesland PG, Messina JC, Mahmoud RA. Breath powered nasal delivery: a new route to rapid headache relief. Headache. 2013;53(S2):72–84.
   PubMedGoogle Scholar
• Rezvani M, Hesari J, Peighambardoust SH, et al. Development and characterization of nanostructured pharmacosomal mesophases: an innovative delivery system for bioactive peptides. Adv Pharm Bull. 2018;8(4):609–615.
   PubMed Web of Science ®Google Scholar
• Graziottin A. Safety, efficacy and patient acceptability of the combined estrogen and progestin transdermal contraceptive patch: a review. Patient Prefer Adherence. 2008;2:357–367.
   PubMedGoogle Scholar
• Stephanie W, Hill C, Ricks ML, et al. The scope and impact of mobile health clinics in the United States: a literature review. Int J Equity Health. 2017;16(1):1–12.
   PubMedGoogle Scholar
• Balducci AG, Magosso E, Colombo G, et al. From tablets to pharmaceutical nanotechnologies: innovation in drug delivery strategies for the administration of antimalarial drugs. J Drug Delivery Sci Technol. 2016;32:167–173.
   Web of Science ®Google Scholar
• Moreira M, Sarraguça M. How can oral paediatric formulations be improved? A challenge for the XXI century. Int J Pharm. 2020;590:119905.
   PubMedGoogle Scholar
• Charlton V, Rid A. Innovation as a value in healthcare priority-setting: the UK experience. Soc Justice Res. 2019;32(2):208–238.
   Web of Science ®Google Scholar
• Belloso WH. On innovation. Ther Innov Regul Sci. 2020;54(5):1068–1075.
   PubMed Web of Science ®Google Scholar
• Henshall C, Schuller T. Health technology assessment, value-based decision making, and innovation. Int J Technol Assess Health Care. 2013;29(4):353–359.
   PubMed Web of Science ®Google Scholar
• Kelly CJ, Young AJ. Promoting innovation in healthcare. Future Healthc J. 2017;4(2):121–125.
   PubMedGoogle Scholar
• Monia M. Value of innovation for hematologic malignancies. J Med Econ. 2016;19(5):487–489.
   PubMed Web of Science ®Google Scholar
• Toskin I, Blondeel K, Peeling RW, et al. Advancing point of care diagnostics for the control and prevention of STIs: the way forward. Sex Transm Infect. 2017;93(S4):S81–S88.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Wegner SE. Measuring value in health care: the times, they are a changin. N C Med J. 2016;77(4):276–278.
   PubMedGoogle Scholar
• Porter ME. What is value in health care. N Engl J Med. 2010;363(26):2477–2481.
   PubMed Web of Science ®Google Scholar
• Claxton K, Longo R, Longworth L, et al. The value of innovation [Internet]; 2009.
   Google Scholar
• Dixit S, Goldberg RA. Framework for demonstrating the value of medical innovation; 2019.
   Google Scholar
• Drummond M, Tarricone R, Torbica A. Assessing the added value of health technologies: reconciling different perspectives. Value Health. 2013;16(1 Suppl):S7–S13.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019;22(6):661–668.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Jackson T, Paul D, et al. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness Threshold; 2019.
   Google Scholar
• Jonsson B, Hampson G, Michaels J, et al. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. Eur J Health Econ. 2019;20(3):427–438.
   PubMed Web of Science ®Google Scholar
• Mazzucato M, Roy V. Rethinking value in health innovation:from mystifications towards prescriptions. J Econo Policy Reform. 2019;22(2):101–119.
   Web of Science ®Google Scholar
• Moreno SG, Ray JA. The value of innovation under value-based pricing. J Mark Access Health Policy. 2016;2016:4.
   Google Scholar
• Rejon-Parrilla JC, Espin J, Epstein D. How innovation can be defined, evaluated and rewarded in health technology assessment. Health Econ Rev. 2022;12(1):1–11.
   PubMed Web of Science ®Google Scholar
• Dilla T, Lizan L, Paz S, et al. Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. Patient Prefer Adherence. 2016;10:1–7.
   PubMed Web of Science ®Google Scholar
• Iskrov G, Greenberg D, Yakimov I, et al. What is the value of innovative pharmaceutical therapies in oncology and hematology? A willingness-to-Pay study in Bulgaria. Value Health Reg Issues. 2019;19:157–162.
   PubMedGoogle Scholar
• Shtrichman R, Conrad S, Schimo K, et al. Use of a digital medication management system for effective assessment and enhancement of patient adherence to therapy (ReX): feasibility study. JMIR Hum Factors. 2018;5(4):e10128.
   PubMedGoogle Scholar
• Virchow JC, Akdis CA, Darba J, et al. A review of the value of innovation in inhalers for COPD and asthma. J Mark Access Health Policy. 2015;3:28760.
   PubMedGoogle Scholar
• Snider JT, Batt K, Wu Y, et al. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma. Am J Manag Care. 2017;23(10):e340–e6.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Dieterich D, et al. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: the quality-adjusted cost of care. Medicine. 2016;95(41):e5048.
   PubMed Web of Science ®Google Scholar
• Jommi C, Armeni P, Costa F, et al. Implementation of value-based pricing for medicines. Clin Ther. 2020;42(1):15–24.
   PubMed Web of Science ®Google Scholar
• Angelis A, Naci H, Hackshaw A. Recalibrating health technology assessment methods for cell and gene therapies. Pharmacoeconomics. 2020;38(12):1297–1308.
   PubMed Web of Science ®Google Scholar
• Lakdawalla D, Shafrin J, Lucarelli C, et al. Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains. Health Aff. 2015;34(4):555–561.
   PubMed Web of Science ®Google Scholar
• Huber M, Knottnerus JA, Green L, et al. How should we define health? BMJ. 2011;343:d4163.
   PubMed Web of Science ®Google Scholar
• Kolchinsky P. The great American drug deal: a new prescription for innovative and affordable medicines. Evelexa Press; 2020. ISSN:1733058915. 2020.
   Google Scholar